Management of metastatic castration-resistant prostate cancer has changed markedly over the last decade with major shifts in the treatment paradigm, although ultimately still will progress despite currently available therapies.
The sequencing or combination of these agents is an area of active investigation, since definitive prospective randomized trials to define the optimal choice of drug sequence have yet to be done or resulted. This review will highlight pivotal trials for currently approved therapies for metastatic castration-resistant prostate cancer and a suggestion for sequencing of these agents, as well as highlighting investigations using novel therapies for advanced prostate cancer.
Future Oncol. 2015 Aug 14:1-9. [Epub ahead of print]
El-Bahesh E1, Finianos A1, Alfaraj A2, Aragon-Ching JB1.
1 INOVA Comprehensive Cancer & Research Institute, 8505 Arlington Blvd, Ste 100, Fairfax, VA 22031, USA.
2 Department of Medicine, George Washington University Medical Center, 2150 Pennsylvania Ave., NW, Washington, DC 20037, USA.